Complete Filing Data
Rapport Therapeutics, Inc. reported Net Income Loss of -$111.48 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Rapport Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income * | -$111.5M | -$78.3M | -$34.8M |
| Research And Development Expense | $94.8M | $60.9M | $28.0M |
| Operating Income Loss | -$125.1M | -$83.1M | -$36.2M |
| Operating Expenses | $125.1M | $83.1M | $36.2M |
| Nonoperating Income Expense | $13.6M | $4.7M | $1.4M |
| General And Administrative Expense | $30.3M | $22.1M | $8.2M |
| Comprehensive Income Net Of Tax | -$110.4M | -$78.8M | -$34.8M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $1.1M | -$526.0K | $4.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$78.3M | -$34.8M | |
| Income Tax Expense Benefit | $0.00 | $10.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$26.9M | -$26.7M | -$24.1M | -$17.5M | -$18.1M | -$22.7M | -$8.7M | -$6.4M | -$6.1M |
| Research And Development Expense | $22.3M | $22.7M | $19.6M | $15.5M | $15.7M | $12.5M | $7.6M | $4.7M | |
| Operating Income Loss | -$30.0M | -$29.5M | -$27.1M | -$21.6M | -$20.8M | -$17.1M | -$9.6M | -$6.6M | |
| Operating Expenses | $30.0M | $29.5M | $27.1M | $21.6M | $20.8M | $17.1M | $9.6M | $6.6M | |
| Nonoperating Income Expense | $3.1M | $2.8M | $3.0M | $4.1M | $2.7M | -$5.6M | $856.0K | $221.0K | |
| General And Administrative Expense | $7.7M | $6.8M | $7.5M | $6.1M | $5.1M | $4.6M | $2.0M | $1.9M | |
| Comprehensive Income Net Of Tax | -$26.7M | -$26.7M | -$23.6M | -$17.0M | -$18.1M | -$22.8M | -$8.7M | -$6.4M | |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $221.0K | $19.0K | $427.0K | $583.0K | -$23.0K | -$164.0K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$17.5M | -$18.1M | -$8.7M | -$6.4M | |||||
| Income Tax Expense Benefit | $1.0K | $2.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $484.7M | $305.4M | -$25.6M | -$10.1M |
| Oci Equity Method Investment After Tax Parent | $1.1M | -$526.0K | $4.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $52.8M | $56.9M | $70.3M | $31.2M |
| Cash And Cash Equivalents At Carrying Value | $52.6M | $56.8M | $70.2M | |
| Restricted Cash Current | $105.0K | $105.0K | $85.0K | |
| Short Term Investments | $437.9M | $248.5M | $77.3M | |
| Retained Earnings Accumulated Deficit | -$235.2M | -$123.7M | -$45.4M | |
| Property Plant And Equipment Net | $3.0M | $3.5M | $1.9M | |
| Prepaid Expense And Other Assets Current | $7.9M | $4.4M | $3.3M | |
| Other Assets Noncurrent | $985.0K | $160.0K | $551.0K | |
| Operating Lease Right Of Use Asset | $9.9M | $1.4M | $2.1M | |
| Operating Lease Liability Noncurrent | $8.7M | $739.0K | $1.5M | |
| Operating Lease Liability Current | $2.8M | $737.0K | $670.0K | |
| Liabilities Current | $19.0M | $8.8M | $8.8M | |
| Liabilities And Stockholders Equity | $512.4M | $314.9M | $155.4M | |
| Liabilities | $27.8M | $9.5M | $14.5M | |
| Common Stock Value | $48.0K | $37.0K | $4.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$4.2M | -$13.3M | $39.1M | |
| Assets Current | $498.6M | $309.8M | $150.9M | |
| Assets | $512.4M | $314.9M | $155.4M | |
| Additional Paid In Capital Common Stock | $719.3M | $429.7M | $19.8M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $546.0K | -$522.0K | $4.0K | |
| Accrued Liabilities Current | $12.1M | $6.1M | $5.6M | |
| Accounts Payable Current | $4.2M | $2.0M | $2.5M | |
| Operating Lease Right Of Use Asset Amortization Expense | $2.0M | $642.0K | $206.0K | |
| Deferred Offering Costs | $177.0K | |||
| Accretion Amortization Of Discounts And Premiums Investments | $1.4M | $3.2M | $75.0K | |
| Change In Fair Value Of Preferred Stock Tranche Right Liability | $0.00 | $7.4M | $1.1M | |
| Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 | $20.0K | $172.0K | $123.0K | |
| Preferred Stock Value | $0.00 | $0.00 | ||
| Conversion Of Series B Convertible Preferred Stock To Common Stock Upon Closing Of The Initial Public Offering | $145.3M | |||
| Conversion Of Series A Convertible Preferred Stock To Common Stock Upon Closing Of The Intial Public Offering | $89.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $511.6M | $263.5M | $285.8M | $323.1M | $336.9M | -$39.6M | -$13.1M | -$9.4M | -$4.0M | ||
| Oci Equity Method Investment After Tax Parent | $221.0K | $19.0K | $427.0K | $583.0K | -$23.0K | -$164.0K | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $251.5M | $55.2M | $57.7M | $39.4M | $110.3M | $74.4M | $159.4M | $79.5M | |||
| Cash And Cash Equivalents At Carrying Value | $251.4M | $55.1M | $57.6M | $39.3M | $110.2M | $74.3M | $159.4M | $79.5M | |||
| Restricted Cash Current | $105.0K | $105.0K | $105.0K | $105.0K | $105.0K | $105.0K | |||||
| Short Term Investments | $261.7M | $205.4M | $227.8M | $281.3M | $226.0M | ||||||
| Retained Earnings Accumulated Deficit | -$201.5M | -$174.5M | -$147.8M | -$103.8M | -$86.2M | ||||||
| Property Plant And Equipment Net | $3.1M | $3.2M | $3.4M | $3.4M | $3.5M | ||||||
| Prepaid Expense And Other Assets Current | $7.5M | $9.7M | $5.5M | $5.2M | $4.4M | ||||||
| Other Assets Noncurrent | $1.1M | $1.0M | $211.0K | $189.0K | $189.0K | ||||||
| Operating Lease Right Of Use Asset | $10.5M | $11.0M | $7.5M | $1.6M | $1.8M | ||||||
| Operating Lease Liability Noncurrent | $9.4M | $10.1M | $6.8M | $931.0K | $1.1M | ||||||
| Operating Lease Liability Current | $2.5M | $1.8M | $1.0M | $720.0K | $703.0K | ||||||
| Liabilities Current | $14.3M | $11.9M | $9.4M | $7.1M | $8.1M | ||||||
| Liabilities And Stockholders Equity | $535.3M | $285.5M | $302.1M | $331.1M | $346.1M | ||||||
| Liabilities | $23.7M | $22.0M | $16.2M | $8.0M | $9.2M | ||||||
| Common Stock Value | $48.0K | $37.0K | $37.0K | $36.0K | $36.0K | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $799.0K | $4.1M | |||||||||
| Assets Current | $520.7M | $270.2M | $291.0M | $325.9M | $340.7M | ||||||
| Assets | $535.3M | $285.5M | $302.1M | $331.1M | $346.1M | ||||||
| Additional Paid In Capital Common Stock | $712.9M | $438.1M | $433.7M | $426.4M | $423.3M | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $145.0K | -$76.0K | -$95.0K | $400.0K | -$183.0K | ||||||
| Accrued Liabilities Current | $8.6M | $6.9M | $6.2M | $5.1M | $5.5M | ||||||
| Accounts Payable Current | $3.2M | $3.2M | $2.1M | $1.3M | $1.9M | ||||||
| Operating Lease Right Of Use Asset Amortization Expense | $411.0K | $156.0K | |||||||||
| Deferred Offering Costs | $262.0K | $0.00 | $0.00 | $1.4M | $1.5M | $6.0K | $108.0K | ||||
| Accretion Amortization Of Discounts And Premiums Investments | $436.0K | $978.0K | |||||||||
| Change In Fair Value Of Preferred Stock Tranche Right Liability | $7.4M | ||||||||||
| Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 | $847.0K | ||||||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Conversion Of Series B Convertible Preferred Stock To Common Stock Upon Closing Of The Initial Public Offering | $145.3M | ||||||||||
| Conversion Of Series A Convertible Preferred Stock To Common Stock Upon Closing Of The Intial Public Offering | $89.5M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $18.9M | $10.2M | $3.5M |
| Payments To Acquire Property Plant And Equipment | $616.0K | $2.4M | $1.6M |
| Net Cash Provided By Used In Operating Activities | -$87.5M | -$64.8M | -$27.2M |
| Net Cash Provided By Used In Investing Activities | -$187.5M | -$170.1M | -$78.9M |
| Net Cash Provided By Used In Financing Activities | $270.8M | $221.6M | $145.1M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $3.6M | $1.9M | $3.2M |
| Increase Decrease In Other Operating Assets | $791.0K | -$83.0K | $240.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $6.2M | $371.0K | $5.4M |
| Increase Decrease In Accounts Payable | $2.2M | -$346.0K | $856.0K |
| Depreciation Depletion And Amortization | $1.0M | $839.0K | $112.0K |
| Increase Decrease In Operating Lease Liabilities | $491.0K | $670.0K | $144.0K |
| Payments To Acquire Investments | $354.8M | $377.5M | $77.2M |
| Proceeds From Sale Maturity And Collections Of Investments | $167.9M | $209.8M | |
| Proceeds From Stock Options Exercised | $1.3M | $7.0K | |
| Proceeds From Initial Public Offering And Concurrent Private Placement Net Of Underwriter Discounts And Commissions And Deferred Offering Costs | $157.7M | ||
| Payments For Repurchase Of Unvested Restricted Common Stock | $1.0K | -$4.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Share Based Compensation | $4.0M | $1.5M |
| Payments To Acquire Property Plant And Equipment | $291.0K | $1.1M |
| Net Cash Provided By Used In Operating Activities | -$20.2M | -$17.6M |
| Net Cash Provided By Used In Investing Activities | $21.0M | -$41.9M |
| Net Cash Provided By Used In Financing Activities | $5.0K | $63.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $825.0K | $2.1M |
| Increase Decrease In Other Operating Assets | $51.0K | -$27.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $331.0K | $181.0K |
| Increase Decrease In Accounts Payable | $185.0K | -$1.1M |
| Depreciation Depletion And Amortization | $244.0K | $152.0K |
| Increase Decrease In Operating Lease Liabilities | $73.0K | $161.0K |
| Payments To Acquire Investments | $43.2M | $44.8M |
| Proceeds From Sale Maturity And Collections Of Investments | $64.6M | $3.9M |
| Proceeds From Stock Options Exercised | $6.0K | |
| Proceeds From Initial Public Offering And Concurrent Private Placement Net Of Underwriter Discounts And Commissions And Deferred Offering Costs | ||
| Payments For Repurchase Of Unvested Restricted Common Stock | $1.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 38.9M | 20.7M | 1.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 38.9M | 20.7M | 1.5M |
| Earnings Per Share Diluted | $-2.86 | $-3.78 | $-23.10 |
| Earnings Per Share Basic | $-2.86 | $-3.78 | $-23.10 |
| Common Stock Shares Outstanding | 47.8M | 36.6M | 4.2M |
| Common Stock Shares Issued | 47.8M | 36.6M | 4.2M |
| Common Stock Shares Authorized | 500.0M | 500.0M | 250.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 37.9M | 35.4M | 35.3M | 34.9M | 10.7M | 2.0M | 1.5M | 1.4M | |
| Weighted Average Number Of Diluted Shares Outstanding | 37.9M | 35.4M | 35.3M | 34.9M | 10.7M | 2.0M | 1.5M | 1.4M | |
| Earnings Per Share Diluted | $-0.71 | $-0.75 | $-0.68 | $-0.50 | $-1.70 | $-11.07 | $-5.70 | $-4.45 | |
| Earnings Per Share Basic | $-0.71 | $-0.75 | $-0.68 | $-0.50 | $-1.70 | $-11.07 | $-5.70 | $-4.45 | |
| Common Stock Shares Outstanding | 47.7M | 36.5M | 36.5M | 36.6M | 36.6M | ||||
| Common Stock Shares Issued | 47.7M | 36.5M | 36.5M | 36.6M | 36.6M | ||||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 0.00 | |||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $18.9M | $10.2M | $3.5M |
| Investment Income Interest | $13.6M | $12.1M | $2.5M |
| Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | $7.3M | ||
| Stock Issued During Period Value New Issues | $269.4M | $140.9M | |
| Stock Issued During Period Value Stock Options Exercised | $1.3M | $7.0K | |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $54.0K | ||
| Stock Issued During Period Value Private Placement | $16.7M | ||
| Stock Repurchased During Period Value | $1.0K | $4.0K | |
| Stock Issued During Period Shares Stock Options Exercised | 192.9K | 3.7K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.7M | $4.4M | $4.0M | $3.2M | $2.4M | $1.5M | $945.0K | $723.0K | |
| Investment Income Interest | $3.1M | $2.8M | $3.0M | $4.1M | $2.7M | $1.8M | $856.0K | $221.0K | |
| Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments | $7.3M | $2.9M | $11.5M | ||||||
| Stock Issued During Period Value New Issues | $269.4M | $140.9M | |||||||
| Stock Issued During Period Value Stock Options Exercised | $635.0K | $6.0K | |||||||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $859.0K | $30.0K | $24.0K | ||||||
| Stock Issued During Period Value Private Placement | $16.7M | ||||||||
| Stock Repurchased During Period Value | $1.0K | ||||||||
| Stock Issued During Period Shares Stock Options Exercised | 3.2K |
Most recent annual filing with the SEC: March 10, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.